Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
Key Highlights
- ➤Clearmind completes patient enrollment for Part C of CMND-100 Phase I/IIa trial
- ➤Part C evaluates multiple-dose safety, tolerability, and pharmacokinetic profile
- ➤CMND-100 previously entered first patient cohort in Part B for moderate-to-severe AUD
- ➤Part A produced encouraging safety and tolerability data in healthy volunteers
Expert Statements
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine
“The successful completion of Part C enrollment demonstrates the continued momentum of our CMND-100 program and represents another important milestone for Clearmind”
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine
“The data generated in this cohort is expected to further enhance our understanding of CMND-100’s safety, tolerability, and pharmacokinetic profile to help support the advancement of our proprietary non-hallucinogenic treatment candidate toward future development milestones.”
Vancouver, Canada, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the successful completion of patient enrollment for Part C of its ongoing Phase I/IIa clinical trial evaluating CMND-100.
The completion of patient enrollment for Part C marks another important milestone in Clearmind’s clinical development program and reflects the continued strong execution of its Phase I/IIa trial. The achievement follows the successful enrollment of the first cohort in Part B, representing the first clinical evaluation of CMND-100 in patients with moderate-to-severe AUD, and builds on the encouraging safety and tolerability data from Part A in healthy volunteers.
Get started
Create a free account to read the full story.
